## **1** Characterizing Potential Interaction Between Respiratory Syncytial Virus

## 2 and Seasonal Influenza in the U.S.

- 3 Short Title: Potential interactions of co-circulating respiratory viral pathogens
- 4 Jiani Chen<sup>ab</sup>, Deven V. Gokhale<sup>ac</sup>, Liang Liu<sup>bd</sup> Pejman Rohani<sup>abce</sup>, Justin Bahl<sup>abef\*</sup>
- 5 a. Center for Ecology of Infectious Diseases, University of Georgia, Athens, GA, 30602
- 6 b. Institute of Bioinformatics, University of Georgia, Athens, GA 30602
- 7 c. Odum School of Ecology, University of Georgia, Athens, GA 30602
- 8 d. Department of Statistics, University of Georgia, Athens, GA 30602
- 9 e. Department of Infectious Diseases, University of Georgia, Athens, GA 30602
- 10 f. Department of Epidemiology and Biostatistics, University of Georgia, Athens, 30602

11

12	*Email	:	justin.bal	hl(	auga.	edu
----	--------	---	------------	-----	-------	-----

13

14

l

## 15 Abstract

16 RSV and seasonal influenza are two of the most important causes of respiratory infection that 17 consistently peak during winter months in the U.S. Here, we characterized the circulation of 18 these viruses in the U.S. with weekly positive case reports and genetic surveillance and used a 19 mathematical modeling approach to explore their potential interaction at an HHS regional level. 20 Our analyses showed RSV and seasonal influenza co-circulate with various relatively epidemic 21 sizes and seasonal overlaps across seasons and regions. We found RSV might have different 22 evolutionary dynamics compared to seasonal influenza, with local persistence may play a role in 23 underlying annual epidemics. Our analysis supports a competitive interaction between RSV and 24 seasonal influenza in most HHS regions and we speculate that cross-immunity after infection 25 might be the major driver of viral competition. Together, our work supports the competition 26 between RSV and seasonal influenza across the U.S. at a population level. Our findings are 27 important for the future development of protective strategies against these respiratory viruses. 28 Introduction 29 Interaction among infectious diseases has been very well documented in various polymicrobial

disease systems [1]. In the context of respiratory infections, a well-known example is the association between the influenza virus and the bacterium pneumococcus, driven by enhanced susceptibility to secondary bacterial colonization subsequent to influenza infection [2][3][4]. Another important example comes from the 2009 influenza A pandemic (H1N1pdm09), with data from several European countries indicating that the spread of the virus might have been interrupted by the annual autumn rhinovirus epidemic [5]. These pathogen-pathogen interactions may lead to cooperation or competition, and their co-occurrence within the same host population

37 can profoundly alter the pathogenesis and spread of infectious diseases with substantial public38 health consequences [6].

39

40 Respiratory Syncytial Virus (RSV) and seasonal influenza virus (Flu) are two of the most 41 important causes of respiratory infection [7][8][9]. Both RSV and seasonal influenza activity 42 consistently peak during winter months in the US. However, the relative disease burden and 43 similarity between the epidemic timing of these viruses vary substantially among regions and 44 seasons [9], [10]. The burden of influenza varies from season to season, depending in part on the 45 dominant virus type or subtypes in circulation [11]. Influenza subtypes A/H3N2 and A/H1N1 46 (Flu A) have become the leading cause of seasonal influenza illness and death in the U.S. over 47 the last 50 years [12]. Additionally, two distinct lineages of the influenza B (Flu B) virus, 48 Victoria and Yamagata, co-circulate or alternate with Flu A and have received greater attention 49 in recent years [13]. Intensive studies of the molecular evolution of the influenza virus have 50 provided important insights into its seasonal emergence and spread in human populations 51 [11][14][12][13]. Similar to seasonal influenza, two distinct antigenic subgroups of RSV have 52 been identified, RSV-A and RSV-B, which show clear phylogenetic divergence. Genotype ON 53 (RSV-A) and BA (RSV-B) are the two most prevalent RSV genotypes that are circulating in the 54 U.S. in recent years [15][16], [17]. However, the molecular epidemiology of RSV is largely 55 unknown both on local and global scales [18]. Since RSV and seasonal influenza have similar 56 seasonality and clinical presentation, researchers often try to extrapolate knowledge gleaned from the study of seasonal influenza to RSV to understand viral dynamics and develop protective 57 58 strategies against these respiratory viruses-induced illnesses together [19]. Therefore, elucidating 59 the exact nature of the interaction between RSV and seasonal influenza can greatly enhance our

60 ability to forecast future epidemics, and substantially inform the development and

- 61 implementation of control strategies.
- 62

63 Both biological and epidemiological studies suggest potential competitive interaction between 64 RSV and seasonal influenza [20]. The proposed biological mechanism for the competition 65 between these viruses is the activation of the innate "antiviral response" by an infection that can 66 inhibit further or subsequent infection of another virus, resulting in a period of cross-protection 67 during or after infection [18], [21]. Epidemiological data show that when rates of infection with 68 RSV are high, influenza infections are low; the converse is also true [22]. The interaction 69 between respiratory viruses has the potential to impact virus genetic diversity and epidemics 70 pattern and therefore would lead to the observed patterns in phylogenetics or surveillance data 71 [11], [25]. Previous studies have demonstrated the application of dynamic modeling to test 72 biological hypotheses on pathogen interaction mechanisms and it could be used to infer the interaction between RSV and seasonal influenza [23]. However, very few studies examine the 73 74 potential interaction between RSV and seasonal influenza on a population level, and the explicit 75 mechanism of their interaction has not been well-studied.

76

In this study, we initially carry out a phylogenetic analysis to elucidate differences in the evolutionary trajectories of RSV and seasonal influenza. We then apply a seasonally forced, twopathogen, mechanistic transmission model to explicitly investigate the nature of ecological interference between RSV and seasonal influenza and quantify its effects in driving transmission dynamics in different regions in the U.S. Our analysis provides evidence of the potential negative

- 82 interaction of RSV and seasonal influenza on the ecological scale and the cross-immunity after
- 83 infection might be an important mechanism.
- 84
- 85 **Results**
- 86

### 87 Seasonality overlaps between RSV and seasonal influenza

88 Different relative epidemic sizes and peaking times of RSV and seasonal influenza can be

89 observed across different HHS regions in the U.S. (SI Appendix, Fig. S1, represented regions are

90 shown in Fig.1A). We computed the correlation coefficient of these viruses using weekly

91 surveillance reports and found the positive case of RSV and seasonal influenza increased with

92 another (Fig.1B, SI Appendix, Table S1), suggesting epidemic seasonality similarities between

93 these viruses in the U.S. In addition, the magnitude of the correlation between RSV and seasonal

94 influenza are various across HHS regions, with a relatively high value in HHS Regions 6, 7, and

95 10 between RSV and Flu A and in HHS regions 6, 7, and 8 between RSV and Flu B. We further

96 computed the time-lagged correlation of different pairs of viruses (Fig.1C) to measure the

97 temporal association between RSV and seasonal influenza epidemics in the U.S. In our analysis,

98 we observed the maximize correlation with zero to little (positive/negative) time lags in different

99 regions, indicating the seasonality overlap between RSV and seasonal influenza are different

100 across regions and might have different interaction patterns.



102 Fig. 1. Correlation coefficient of RSV and seasonal influenza epidemics in the U.S. A.

103 Weekly RSV and seasonal influenza epidemics in represented HHS regions (HHS Region

104 4,7,8,10). **B.** Correlation coefficient between RSV and seasonal influenza weekly surveillance 105 reports (Table S1). Relative color in HHS regions indicates the normalized correlation 106 coefficient of weekly positive samples of the different pairs of viruses. C. Time-lagged 107 correlation coefficient between RSV and seasonal influenza (Table S2). The time lags (week) 108 that maximize the correlation coefficient in each HHS region are labeled with \*. Negative values 109 indicate a leading correlation and positive values indicate a lagging correlation. Lighter-colored 110 indicate a higher correlation coefficient between two viruses and darker-colored indicate a lower 111 correlation coefficient.

### 112 Population dynamics of RSV and seasonal influenza

113 We characterized the population dynamics of RSV and seasonal influenza using a phylogenetic 114 approach. The phylogenies of seasonal influenza lineages were estimated using Hemagglutinin 115 (HA) gene segments that were collected in the U.S. during the 2011-2019 seasons. The analyses 116 of RSV were based on G gene sequences from northern hemisphere countries in the same period 117 and we focus on genotypes ON and BA. We calculated the time-sliced statistics (Materials and 118 Methods, TMRCA: Time to the most recent ancestor, and Diversity: branch distance between 119 pairs of tips) from RSV and seasonal influenza phylogenies (Fig. 2A). A periodic reduction in 120 TMRCA and diversity across time can be observed from seasonal influenza phylogenies (H1, 121 H3, Victoria, and Yamagata). In contrast, TMRCA and diversity scores of RSV phylogenies 122 increased across time, except for the analysis of BA in recent seasons, which might be due to a 123 lack of RSV sampling during recent sampling times. In addition, Bayesian "Skyride" coalescent 124 reconstructions demonstrate strong periodicity of seasonal influenza viruses, which are 125 correlated with their seasonal epidemic patterns, though we observed very low genetic diversity 126 of Flu B lineages in some years. The population dynamics of RSV did not show seasonal

- 127 fluctuation and both ON and BA genotypes presented peaks from 2011 to 2019 (Fig.2B, Fig.2C).
- 128 These different phylogenetic patterns suggest local persistence may play a role in underlying
- 129 annual epidemics of RSV and influenza strains are under constant negative selection.
- 130



Fig. 2. Population dynamics of RSV and seasonal influenza in the U.S. A. Phylogenies and
corresponding time-slice statistics. The time-slice TMRCA and Diversity are calculated by
breaking the phylogeny into multiple temporal sections. TMRCA, time to the most common
ancestor of all tips within temporal sections. Diversity is the average time to coalescent for pairs
of lineages within temporal sections. TMRCA and Diversity are measured in the unit of years.
Solid lines represent mean values and gray outlines represent 95% CI across MCMC replicates.

138	<b>B.</b> Surveillance curve and reconstructed effective population size of RSV and seasonal influenza
139	using GMRF Bayesian "Skyride" analysis. Solid lines represent mean values and outlines
140	represent 95% CI across MCMC replicates.
141	
142	We computed the correlation coefficient using these estimated time series effective population
143	sizes of RSV and seasonal influenza to explore their potential association at the virus population
144	level (SI Appendix, Table S2). Significant negative correlation coefficients can be observed
145	between RSV and seasonal influenza strains: RSV-A genotype ON with influenza H3 (CI: -
146	0.513, -0.128), H1 (CI: -0.482, -0.087), and Victoria (CI: -0.482, -0.087); RSV-B genotype BA
147	with influenza H1 (CI: -0.506, -0.138) and Yamagata (CI: -0.564, -0.217), which indicate these
148	viruses might have a negative association.
1.40	
149	
149 150	Potential competition between RSV and seasonal influenza
149 150 151	<b>Potential competition between RSV and seasonal influenza</b> The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the
<ul><li>149</li><li>150</li><li>151</li><li>152</li></ul>	Potential competition between RSV and seasonal influenza The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission
<ul> <li>149</li> <li>150</li> <li>151</li> <li>152</li> <li>153</li> </ul>	Potential competition between RSV and seasonal influenza         The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the         co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission         model to investigate the potential competition between RSV and seasonal influenza (SI
<ul> <li>149</li> <li>150</li> <li>151</li> <li>152</li> <li>153</li> <li>154</li> </ul>	Potential competition between RSV and seasonal influenza         The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the         co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission         model to investigate the potential competition between RSV and seasonal influenza (SI         Appendix Fig.S4, Table S3, Table S4) in the U.S. This model accommodates two mechanisms of
<ul> <li>149</li> <li>150</li> <li>151</li> <li>152</li> <li>153</li> <li>154</li> <li>155</li> </ul>	Potential competition between RSV and seasonal influenza         The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the         co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission         model to investigate the potential competition between RSV and seasonal influenza (SI         Appendix Fig.S4, Table S3, Table S4) in the U.S. This model accommodates two mechanisms of         competition between pathogens. Competition may arise through the inhibition of co-infection,
<ul> <li>149</li> <li>150</li> <li>151</li> <li>152</li> <li>153</li> <li>154</li> <li>155</li> <li>156</li> </ul>	Potential competition between RSV and seasonal influenza         The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the         co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission         model to investigate the potential competition between RSV and seasonal influenza (SI         Appendix Fig.S4, Table S3, Table S4) in the U.S. This model accommodates two mechanisms of         competition between pathogens. Competition may arise through the inhibition of co-infection,         which is modeled by scaling the transmission rates of secondary infections with parameter ψ. In
<ol> <li>149</li> <li>150</li> <li>151</li> <li>152</li> <li>153</li> <li>154</li> <li>155</li> <li>156</li> <li>157</li> </ol>	Potential competition between RSV and seasonal influenza The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission model to investigate the potential competition between RSV and seasonal influenza (SI Appendix Fig.S4, Table S3, Table S4) in the U.S. This model accommodates two mechanisms of competition between pathogens. Competition may arise through the inhibition of co-infection, which is modeled by scaling the transmission rates of secondary infections with parameter $\psi$ . In addition, following infection with one pathogen, individuals may gain short-term cross-immunity
<ol> <li>149</li> <li>150</li> <li>151</li> <li>152</li> <li>153</li> <li>154</li> <li>155</li> <li>156</li> <li>157</li> <li>158</li> </ol>	Potential competition between RSV and seasonal influenza The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission model to investigate the potential competition between RSV and seasonal influenza (SI Appendix Fig.S4, Table S3, Table S4) in the U.S. This model accommodates two mechanisms of competition between pathogens. Competition may arise through the inhibition of co-infection, which is modeled by scaling the transmission rates of secondary infections with parameter $\psi$ . In addition, following infection with one pathogen, individuals may gain short-term cross-immunity against another pathogen and can be similarly modeled by scaling the force of secondary
<ul> <li>149</li> <li>150</li> <li>151</li> <li>152</li> <li>153</li> <li>154</li> <li>155</li> <li>156</li> <li>157</li> <li>158</li> <li>159</li> </ul>	Potential competition between RSV and seasonal influenza The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission model to investigate the potential competition between RSV and seasonal influenza (SI Appendix Fig.S4, Table S3, Table S4) in the U.S. This model accommodates two mechanisms of competition between pathogens. Competition may arise through the inhibition of co-infection, which is modeled by scaling the transmission rates of secondary infections with parameter $\psi$ . In addition, following infection with one pathogen, individuals may gain short-term cross-immunity against another pathogen and can be similarly modeled by scaling the force of secondary infection by $\chi$ . Changing the value of these two parameters can influence the timing, magnitude,

161



162

Fig. 3. Simulation study to examine the effects of the proportion of inhibition of co-infection ( $\psi$ ) and cross-immunity after infection ( $\chi$ ) using a two-pathogen transmission model. A. Changes in relative peak case ratio and the relative time of peaks based on the values  $\psi$  and  $\chi$  in the model. **B.** Simulated trajectories resulting from parameter values of  $\psi$  and  $\chi$  selected at points a, b, c, and d in A.

168

169 We fit this model to RSV and type-specific seasonal influenza (Flu A or Flu B) incidence data

170 that are collected from 10 HHS Regions from 2014 to 2017 and use Akaike Information

- 171 Criterion (AIC) values to compare four different hypotheses regarding the interaction between
- 172 RSV and seasonal influenza: (1) no interaction ( $\chi = \psi = 1$ ); (2) inhibition of co-infection ( $\psi < \psi = 1$ )

173 1,  $\chi = 1$  ); (3) transient cross-immunity after infection ( $\psi = 1, \chi < 1$ ); and (4) both the 174 inhibition of co-infection and transient cross-immunity ( $\psi < 1, \chi < 1$ )(SI Appendix Table S5). 175 In these analyses, the duration of short-lived cross-protection is fixed at 6 months [24]. We 176 estimated parameters that could optimize the likelihood estimates of the model under each 177 hypothesis in 10 HHS regions (SI Appendix Table S7 to Table S16). The virus-specific 178 simulated trajectories under four hypotheses for 10 HHS regions are shown in SI Appendix, Fig. 179 S5. We found that adding competitive interaction between RSV and seasonal influenza provides 180 a better explanation of the surveillance data in most regions except for HHS Region 8 (SI 181 Appendix, Table S6), and the epidemic trajectories from surveillance data in different HHS 182 regions can be well fit under the corresponding best hypothesis as examined by Root Mean 183 Square Error (RMSE) (SI Appendix, Fig. S6). As described in Table 1, different levels of cross-184 immunity after infection were estimated across HHS regions under the corresponding best hypothesis, and the inhibition of co-infections was also supported in some regions (HHS Regions 185 186 1, 3, 4, 5, 6, 7 for RSV and Flu A, HHS Regions 3, 5, 6, 10 for RSV and Flu B). We used HHS 187 Region 1 as an example region to demonstrate our findings: our analysis suggests RSV and Flu 188 A are fully inhibited to be co-infected and there was also a short-term cross-immunity, with a 189 45% reduction in the infection rate of another pathogen. By fitting the RSV and Flu B 190 surveillance, we found a 39% reduction in the infection of the second virus, and the inhibition of 191 co-infection was not supported (Fig. 4, Table 2).

# 193 Table 1. Competition parameter estimates under the best fit hypothesis for seasons 2014-

## 194 **2018 in 10 HHS regions.**

195

	RSV-	·Flu A	RSV-Flu B		
HHS region	Inhibition of co- Cross-immur		Inhibition of co-	Cross-immunity	
	$infection(\psi)$	after infection( $\chi$ )	infection( $\psi$ )	after infection( $\chi$ )	
1	0	0.55	1	0.64	
2	1	0.69	1	0.72	
3	0	0.59	0	0.8	
4	0.57	0.37	0	0.87	
5	0	0.78	1	0.61	
6	0	0.77	1	0.45	
7	0	0.52	0.95	0.64	
8	1	1	1	1	
9	1	0.79	0.2	0.6	
10	1	0.5	1	0.2	







- 201 regional level weekly case report data. A. The test of the interaction between RSV and Flu A. B.
- 202 The test of the interaction between RSV and Flu B.

# Table 2. Parameters estimates and epidemiological hypotheses evaluation for season 2014 2017 in HHS regions 1

205

Parameter	No interaction	Inhibition of co- infection	Cross-immunity after infection	Inhibition of co- infection and cross-immunity after infection
RSV-Flu A				
$R_0^{RSV}$	1.49	1.46	1.84	1.89
$R_0^{Flu}$	1.37	1.05	1.31	1.27
$b_{RSV}$	0.26	0.33	0.13	0.15
$b_{Flu}$	0.1	0.27	0.17	0.23
$t_0^{RSV}$	0.91	0.93	0.98	0.99
$t_0^{Flu}$	0.1	0.03	0.12	0.11
$\overset{\circ}{\psi}$	1	0	1	0
X	1	1	0.47	0.55
$\delta_{RSV}$	2.49E-04	2.45E-04	2.07E-04	1.97E-04
$\delta_{Flu}$	6.49E-04	1.07E-03	8.94E-04	9.34E-04
loglik	-4946.37	-3966.74	-3673.11	-3463.34
AIC	9908.74	7951.49	7364.22	6946.68
$\Delta AIC$	2962.06	1004.81	417.54	0
RMSE	62.47	52.51	50.36	49.3
RSV-Flu B				
$R_0^{RSV}$	1.49	1.49	1.34	1.36
$R_0^{Flu}$	1	1	1	1.09
$b_{RSV}$	0.26	0.26	0.29	0.3
$b_{Flu}$	0.28	0.32	0.38	0.32
$t_0^{RSV}$	0.91	0.92	0.9	0.9
$t_0^{Flu}$	0.14	0.14	0.16	0.16
$\psi$	1	0	1	0.02
χ	1	1	0.64	0.61
$\delta_{\scriptscriptstyle RSV}$	2.49E-04	2.49E-04	3.33E-04	3.17E-04
$\delta_{Flu}$	2.69E-04	2.69E-04	2.74E-04	2.47E-04
loglik	-1504.85	-1491.16	-1353.99	-1376.56
AIC	3025.7	3000.32	2725.99	2773.13
$\Delta AIC$	299.71	274.33	0	47.14
RMSE	11.14	11.28	11.03	12.06

206

207  $R_0^i$ , reproductive number of pathogen *i*,  $b_i$ , the amplitude of seasonality of pathogen *i*,  $t_0^i$ , the 208 timing of seasonal peak for pathogen *i*.  $\delta_i$ , the case report rate for pathogen *i*. The goodness of fit 209 under different hypotheses was assessed using the Akaike information criterion (AIC),  $\Delta$ AIC is 210 calculated by the difference with the lowest AIC value using the same dataset. RMSE is used to 211 quantify how well the model fits with surveillance data.

212

- 214 We further estimated the credible interval (CI) of the two competitive parameters under the best-
- 215 fit hypothesis in 10 HHS regions (SI Appendix, Fig. S7). As shown in the analysis of HHS
- 216 Region 1 (Fig. 5), changing the values of  $\psi$  have relatively small effects on the likelihood profile
- 217 compared with the strength of cross-protection ( $\chi$ ), and the CI of  $\chi$  can be well identified (RSV
- and Flu A: 0.522, 0. 567, RSV and Flu B: 0.628, 0.638). Our results indicate that short-term
- 219 cross-immunity after the infection might be the major mechanism to explain the competition
- 220 between RSV and seasonal influenza.



221

Fig. 5. Likelihood profile tests of competition interaction parameters for RSV and seasonal influenza, inferred in HHS Region 1 from 2014 to 2017. Plotted in each graph is the likelihood profile for the inhibition of co-inhibition ( $\psi$ ) in green and the cross-immunity after infection ( $\chi$ ) in orange, which are lines connected by repeated likelihood estimates (N =20, shown in colored solid circles). The values within the two dashed lines are within the estimated 95% CI. **A.** The

test of the interaction between RSV and Flu A. B. The test of the interaction between RSV andFlu B.

229

## 230 Discussion

231 In this study, we demonstrate the circulation dynamics of RSV and seasonal influenza in the U.S. 232 and examine their potential competition and mechanism at a population level. Our phylogenetic 233 analyses initially suggest there might be a negative association between RSV and seasonal 234 influenza by studying the correlation of their estimated time-series genetic diversity. We further 235 study this potential negative interaction explicitly by applying a two-pathogen transmission 236 model with HHS regional-level surveillance reports. Taken together, our analyses provide 237 statistical support for the negative interaction between RSV and seasonal influenza after 238 infection.

239

By studying the co-circulation of RSV and seasonal influenza in different regions of the U.S, we confirm the temporal correlation between these viruses. We found there might be little to zero number of weeks of time-lags to maximize the correlation coefficient between RSV and different subtypes of influenza. These differences in relative epidemic peaks of RSV and seasonal influenza across different HHS regions in the U.S suggests they might interact with different severity.

246

247 Phylogenetic analysis can be used to estimate the virus's genetic diversity through time and
248 therefore has the potential to reflect the effects of interactions between viruses. Previous
249 phylogenetic studies of seasonal influenza demonstrated a periodicity in the relative genetic

250 diversity in temperate zones where regional epidemics have coinciding epidemic peaks and 251 seasonal patterns [27]. A similar seasonality of RSV was also reported in multiple Northern 252 Hemisphere countries experiencing a temperate climate, with the annual epidemics starting in the 253 autumn, peaking in winter, and ending in spring [28]–[30]. Therefore, we expect a similar 254 seasonal periodicity in relative genetic diversity could be observed in the RSV phylogenetic 255 analyses with sequences that are collected from available northern hemisphere countries. 256 However, our phylogenetic analyses of RSV suggest a different pattern of seasonal influenza and 257 indicate the potential of regional persistence, which is consistent with previous phylogenetic 258 studies of RSV in other regions [31]-[32], [33]. The antigenic drift of seasonal influenza creates 259 competition among strains, resulting in the emergence of selective forces and previously 260 circulating strains can be prone to local extinction each year [34]. This negative selection 261 including the effect of the vaccine causes rapid influenza population turnover and therefore it 262 only takes a few years for contemporaneous strains to find a common ancestor [35], [36]. In 263 contrast, RSV phylogenies harbor many deep branches in our analysis (Fig. 2). This 264 reconstructed population dynamics of RSV might indicate latency supported by low levels of 265 circulation during the summer season that is not captured by current RSV genomic surveillance 266 [33], and RSV seasonal epidemics could be driven by other ecological factors like humidity, 267 temperature, and human contact or travel [28][37]. These differences between RSV 268 and influenza suggest in phylogenies suggest different protection and vaccine strategies may be 269 needed against these viruses [34][35], [36]. We observe a negative correlation between RSV and 270 seasonal influenza lineages with time series effective population sizes that are estimated from 271 genetic data, which suggests a potentially negative interaction between these viruses on an 272 ecological scale. However, our analyses are limited by the lack of genetic surveillance effort and

more explicit analyses are still needed to study the potential competition between RSV andseasonal influenza.

275

276 Our transmission modeling work provides additional evidence of the negative interaction 277 between RSV across regions and seasonal influenza and further demonstrates the potential 278 mechanism of interaction. We find adding inhibition on co-infection to the model has relatively 279 small effects on epidemic trajectories from a simulation study (Fig.3), and the inhibition on co-280 infection is not supported by the surveillance data from some HHS regions. This might be due to 281 the short infection period of RSV and seasonal influenza, and only a small proportion of the 282 population has the potential to be infected by two viruses simultaneously and therefore do not 283 leave a strong dynamical footprint in population-level weekly surveillance data. In our analyses, 284 there are very few individuals to be infected by RSV and seasonal influenza simultaneously, 285 which is consistent with previous surveillance studies that suggest the observed incidence of co-286 infectivity of RSV and influenza was significantly less than expected [9]. To further confirm our 287 estimation, the exact number of cases with co-infection is needed. In addition, the severities of 288 competition between these viruses across HHS regions are estimated to be different from our 289 analysis. The population structure (e.g. age) in different regions might cause different levels of 290 cross-pathogen immunity [18]. It is also important to note that the surveillance reporting 291 institutions vary across regions, which may result in different levels of competition that are 292 reflected in the surveillance data. These location-specific features need to be considered when 293 generalizing the findings.

295 Much of the previous evidence for the interaction between RSV and seasonal influenza is on an 296 individual, biological level [38][25][24][39][21]. Previous evidence of the interaction of RSV 297 and seasonal influenza on the population level implies that prevention of one could inadvertently 298 lead to an increase in the burden of the other [23][26]. Recent modeling work suggests a 299 competition between RSV and influenza with infection reducing heterologous acquisition by 300 41% for 10 days among children after infection in Nha Trang, Vietnam [40]. We provide 301 additional evidence for the competition between RSV and influenza at the population level in a 302 more diverse region in the U.S. and the level of competition could be differentiated by location. 303 While our findings are consistent with previous experimental studies and modeling work 304 suggests a competitive interaction between RSV and influenza [20][21][41][42], it is important 305 to emphasize social behavioral changes after infection (sequestration during convalescence) with 306 a virus may also play a role [43].

307

308 To simplify the analyses with the transmission model, we assume RSV-influenza interaction is 309 bidirectional and the strength and duration of interaction that influenza exhibits on RSV are the 310 same and vice versa. We do not model RSV and two subtypes of seasonal influenza together 311 because adding another virus would significantly increase the complexity of the model and we 312 believe there is a low chance for individuals to be infected with RSV and two subtypes of 313 seasonal influenza within a short time. To reduce the number of parameters that need to be 314 estimated, we fix the cross-protection period with a relatively long time of 6 months [44] and we 315 assume the cross-immunity could protect the individual to be less likely infected by another 316 pathogen at the same season. Our analysis is also limited by current RSV and seasonal influenza 317 surveillance availability. We are lacking RSV subtype information in the current surveillance

318 support. In addition, the reporting institutions of RSV and seasonal influenza surveillance vary 319 between years, and spikes in detections may reflect increased testing within a given surveillance 320 year. Hence, additional high-quality surveillance data in the future might be able to draw a more 321 reliable conclusion. 322 323 Overall, we characterize the seasonal overlaps and evolutionary dynamics of RSV and seasonal 324 influenza and focus on their potential interaction. Our work highlights the use of mathematical 325 mechanistic models to test the interaction hypothesis of RSV and seasonal influenza. Although 326 more effort is needed, our results suggest a cross-immunity-induced negative interaction of RSV 327 and influenza on the ecological scale and can be identified in surveillance data. This study is 328 helpful to have a better understanding of the different dynamics and the potential interaction 329 between RSV and seasonal influenza, which are critical for predicting the effects of alteration of 330 their ecological balance and designing vaccines against these viruses. 331 332 **Materials and Methods** 333 334 RSV and seasonal influenza surveillance data 335 PCR reports from HHS regional-level surveillance data for RSV that are collected from 2011 to 336 2019 were requested from CDC's National Respiratory and Enteric Virus Surveillance System 337 (NREVSS). HHS regional-level type-specific seasonal influenza (Flu A / Flu B) positive test 338 reports were downloaded from FluView Interactive [45], and the viral surveillance reported by 339 Clinical Labs was used after the year 2015. The national-level surveillance data were aggregated 340 from the reports of 10 HHS regions.

341

### 342 Correlation coefficient estimation

343 To measure the association between RSV and seasonal influenza epidemic, we computed 344 correlation coefficients with weekly surveillance reports of different pairs of viruses in each 345 HHS region in R v4.1. The weekly positive cases / million individuals of each virus were 346 calculated by the estimated population for each HHS region in the given year, which were 347 collected from the U.S. Census Bureau using the "State Population Totals and Components of 348 Change: 2010-2019" data set [46]. We employed the Shapiro-Wilk normality test to test for the 349 normality of the error distribution of the time series being compared. Pearson's correlation 350 coefficient was used to quantify the linear association among the co-circulating viral dynamics 351 and the association was taken to be statistically significant at a p-value < 0.05 in a t-test. The 352 time-lagged correlation coefficient was estimated in R package astsa v1.15 [47].

353

To examine the correlation of the genetic diversity for RSV and seasonal influenza, approx() interpolating function in R was used to generate the effective population sizes of different virus strains at the same time points from 2011-2019 from their corresponding Bayesian "Skyride" analysis. After examining the normality of the data using Shapiro-Wilk normality test, we used Pearson's correlation coefficient test to measure the correlation of RSV and seasonal influenza

### 360 Genetic datasets

361 HA segments of seasonal influenza (H3, H1, Victoria, and Yamagata) were retrieved from the
362 GISAID database spanning the 2011-2019 epidemic seasons (generally considered as the
363 October of the start year through May of the following year) in the U.S. Due to the lack of

364	sampling for RSV in the US and North America regions, RSV G gene sequences (at least 70%
365	length of complete G gene) that are collected from available northern hemisphere countries
366	during the same period were retrieved from the GISAID database. RSV genotypes were
367	determined with a reference dataset using NCBI BLAST [48], [49] and further confirmed with
368	phylogenetic analyses, and sequences belonging to the dominant genotypes "ON" (RSV-A) and
369	"BA" (RSV-B) were selected for the following analysis.

370

371 Nucleotide sequences that belong to each genotype were aligned using MAFFT.v7 [50]

372 separately and initial maximum likelihood (ML) phylogenetic trees were built using RAxML.v8

373 [51]. The temporal signal of each dataset was analyzed using TempEst v1.5.3 [52] and temporal

374 outliers were removed for further studies. These ML phylogenies for seasonal influenza in

different subtypes were further used to subsample to a maximum of 100 isolates in each season

376 using the Phylogenetic Diversity Analyzer (PDA) [53]. These subsampled datasets were used for

the subsequent Bayesian phylogenetic analyses. The final datasets contained 1004 ON1, 769 BA

378 RSV G gene sequences, 867 H3, 871 H1,796 Victoria, and 789 Yamagata HA gene segments of

379 seasonal influenza.

380

## 381 Bayesian phylogenetic analysis

382 Evolutionary dynamics of RSV and seasonal influenza were estimated with a Bayesian

383 phylogenetic approach using BEAST v.1.10.4[54]. A generalized time-reversible nucleotide

384 substitution model with gamma rate heterogeneity was used for the analysis of RSV and the

385 SRD06 codon position model was used for the analysis of seasonal influenza [55][56].

386 Uncorrelated lognormal relaxed clock and GMRF Skyride coalescent model [57] were used to

387	estimate the population dynamics of the virus during each season for both pathogens. At least 4
388	independent MCMC chains of 150-200 million generations were simulated to ensure a sufficient
389	effective sample size (ESS > 200) as diagnosed in Tracer v1.7 [58]. LogCombiner v1.10.4 was
390	used to combine the multiple runs and the Maximum Clade Credibility (MCC) tree was
391	summarized in TreeAnnotator v1.10.4 after the removal of the 10% burn-in. Temporal-sliced
392	descriptive statistics, including TMRCA estimates, diversity measurements, and mean statistics
393	including coalescent rate, diversity, and Tajima's D scores were calculated from BEAST
394	sampled Bayesian phylogenetic trees using the software package PACT v0.9.3 [35].
395	
396	Two pathogen transmission model
397	We applied a two-pathogen transmission model to study the potential interaction of RSV and
398	seasonal influenza [59]. The population is compartmentalized into Susceptible (S), Infectious (I),
399	Cross-protected (C), and Recovered (R) for each pathogen <i>i</i> , ( <i>i</i> $\epsilon$ 1,2)[59], [60]. Transitions
400	among these compartments were governed by the following processes. Susceptible individuals
401	with no immunity are infected at rates $\lambda_i$ and enter the corresponding I compartment. Following
402	the infectious period (with a mean duration of $1/\gamma_i$ ), individuals recover and move to the C
403	compartment, where individuals are fully protected against homologous re-infection and have
404	some cross-immunity against another virus. Individuals then lose this cross-immunity but retain
405	pathogen-specific immunity in moving to the R compartment at rate $\rho$ . Pathogen-specific
406	immunity wanes as individuals become susceptible again at rate $\omega$ . The birth-death rate at each
407	compartment is $\mu$ .
408	

409 We hypothesize that the infection with another pathogen might be less likely either during or 410 after the infection of the first pathogen, corresponding to either the I or C compartments, and 411 therefore we define the infection rate of another pathogen with the potential of reduction. In the I 412 compartment, an interaction corresponds to a reduction in the infection rate of the second 413 pathogen at  $\psi \lambda_i$ , where the inhibition to be co-infected is modeled by scaling the rates of 414 infection using a value between 0 and 1 ( $\psi \in [0,1]$ ). In the C compartment, we similarly model a 415 reduced infection rate  $\chi \lambda_i$  for the second virus, wherein the strength of cross-immunity,  $\chi$ , takes 416 a value between 0 and 1 ( $\chi \in [0,1]$ ). Parameters and estimated values used in the model are 417 shown in SI Appendix, Table S4. In a deterministic setting, the model is described by 16 418 ordinary differential equations (Table S3, Equations for each state can be read directly from SI 419 Appendix, Fig. S3).

420

421 The inhibition of co-infection was modeled by a reduction in the infection rate to the second 422 virus,  $\psi \lambda_i$  ( $\psi \in [0,1]$ ), the equations governing these dynamics are given by:

423 
$$\frac{dX_{SI}}{dt} = \omega_1 X_{RI} + \lambda_2 X_{SS} - \gamma_2 X_{SI} - \psi \lambda_1 X_{SI} - \mu X_{SI} \qquad 1$$

424 
$$\frac{dX_{IS}}{dt} = \lambda_1 X_{SS} + \omega_2 X_{IR} - \gamma_1 X_{IS} - \psi \lambda_2 X_{IS} - \mu X_{IS} \qquad 2$$

425 
$$\frac{dX_{II}}{dt} = \psi \lambda_1 X_{SI} + \psi \lambda_2 X_{IS} - \gamma_1 X_{II} - \gamma_2 X_{II} - \mu X_{II}.$$
 3

426

427 The cross-immunity after the infection was modeled by a reduced infection rate to the second 428 virus  $\chi \lambda_i$  ( $\chi \in [0,1]$ ) at the C compartment:

429 
$$\frac{dX_{IC}}{dt} = \chi \lambda_1 X_{SC} + \gamma_2 X_{II} - \gamma_1 X_{IC} - \rho_2 X_{IC} - \mu X_{IC}$$

430 
$$\frac{dX_{CI}}{dt} = \gamma_1 X_{II} + \chi \lambda_2 X_{CS} - \rho_1 X_{CI} - \gamma_2 X_{CI} - \mu X_{CI}.$$
 5

431 The overall population in this model is the sum of the populations in each compartment:

432

433 
$$N = X_{SS} + X_{SI} + X_{Sc} + X_{SR} + X_{IS} + X_{II} + X_{IC} + X_{IR} + X_{CS} + X_{CI} + X_{CC} + X_{CR} + X_{RS} + X_{RI} + X_{RC} + X_{RR}.$$

434

435 For virus  $i \ (i \in \{1,2\})$  in this model, seasonality in the transmission rate  $(\beta_i(t))$  was

436 incorporated in the transmission model, where  $R_0^i$  is the basic reproductive number,  $b_i$  is the

437 amplitude of seasonality, and  $t_0^i$  is the peak transmission day during the season:

438 
$$\beta_i(t) = \gamma_i R_0^i \left[ 1 + b_i \cos\left(2\pi \frac{t - t_0^i}{T}\right) \right].$$
 7

439 The force of infection depends on the number of individuals infected with the virus *i* and the rate

440 at which cases are imported into the population from external sources  $\eta_i$ .

441
$$\lambda_{1}(t) = \beta_{1}(t) \frac{X_{IS} + X_{II} + X_{IC} + X_{IR} + \eta_{1}}{N}$$

$$X_{CI} + X_{II} + X_{CI} + X_{DI} + \eta_{2}$$
8

$$\lambda_2(t) = \beta_2(t) \frac{X_{SI} + X_{II} + X_{CI} + X_{RI} + \eta_2}{N}.$$

442 The deterministic model was implemented in R using the package "pomp" [61]. For the

443 likelihood-based inference, we generated the observed cumulative number of cases  $(K_i)$ 

444 according to the following equations, where  $\delta_i$  is the case report rate of the virus.

$$\frac{dK_1}{dt} = \delta_1(\gamma_1 X_{IS} + \gamma_1 X_{II} + \gamma_1 X_{IC} + \gamma_1 X_{IR})$$
 10

$$\frac{dK_2}{dt} = \delta_2(\gamma_2 X_{SI} + \gamma_2 X_{II} + \gamma_2 X_{CI} + \gamma_2 X_{RI}).$$
 11

446

We initiated the model with an endemic equilibrium of the non-interacting model ( $\psi = 1, \chi = 1$ ) without seasonality ( $b_1 = 0, b_2 = 0$ ), the first 100 years were discarded as transient dynamics before the likelihood calculation.

450

### 451 Hypothesis testing and parameter estimation

452

453 The model was fit with RSV and type-specific seasonal incidence surveillance that are collected 454 in 10 HHS regions from 2014 to 2017. Maximum-likelihood estimates (MLEs) for the unknown 455 parameters were found using trajectory matching. Differential evolution algorithm (DEoptim) for 456 global optimization implemented in R package "DEoptim" [62] was used to find the estimates 457 that maximize the MLE. We calculated AIC using MLE estimates under each hypothesis. If a 458 model is more than 2 AIC units lower than another, we then consider it significantly better. 459 RMSE was calculated to quantify how well the model fits with surveillance data. As proof of 460 concept, we performed an out-of-sample simulation to demonstrate the suitability of the MLE 461 model; that is, we generated the forecast for the following season of the MLE model with the 462 estimated parameters and then compare the simulated cases with RSV and seasonal influenza 463 surveillance that are collected in each HHS region.

464

We performed a simulation study to estimate the uncertainty of the competitive interaction parameters. We created likelihood profiles for the respective parameters by fitting a smooth line through the log of repeated likelihood estimates in which the respective parameter is a fixed value. The 95% CI is taken to  $\chi_1^2(0.95)/2 \approx 1.92$  log-likelihood units below the maximum likelihood estimates using the  $\chi^2$  distribution.

470			
471	Data	availability	
472			
473	Sour	ce code and data have been deposited on GitHub: <u>https://github.com/JianiC/RSV_flu</u>	
474	The (	GISAID accession number of RSV and seasonal influenza sequence of this study are	
475	avail	able in supplementary materials.	
476			
477	Ackr	nowledgments	
478			
479	We a	acknowledge the RSV surveillance data from the NREVSS team and subtype-specific	
480	seaso	onal influenza surveillance data from the CDC's FluView Interactive. We acknowledge the	
481	originating and submitting laboratories for our use of sequences from the GISAID's EpiFlu and		
482	EpiR	SV Database.	
483			
484	Refe	rences	
485			
486	[1]	B. M. Peters, M. A. Jabra-Rizk, G. A. O'May, J. W. Costerton, and M. E. Shirtliff,	
487		"Polymicrobial interactions: impact on pathogenesis and human disease," Clin. Microbiol.	
488		Rev., vol. 25, no. 1, pp. 193–213, Jan. 2012, doi: 10.1128/CMR.00013-11.	
489	[2]	S. Shrestha, B. Foxman, D. M. Weinberger, C. Steiner, C. Viboud, and P. Rohani,	
490		"Identifying the interaction between influenza and pneumococcal pneumonia using	
491		incidence data.," Sci. Transl. Med., vol. 5, no. 191, p. 191ra84, Jun. 2013, doi:	
492		10.1126/scitranslmed.3005982.	

493	[3]	M. Li	psitch et al.,	"Estimating	Rates of	Carriage A	Acquisition	1 and	Clearance and	l
						2)				

- 494 Competitive Ability for Pneumococcal Serotypes in Kenya With a Markov Transition
- 495 Model," *Epidemiology*, vol. 23, no. 4, 2012, [Online]. Available:
- 496 https://journals.lww.com/epidem/Fulltext/2012/07000/Estimating Rates of Carriage Ac
- 497 quisition\_and.2.aspx.
- 498 [4] L. Opatowski *et al.*, "Assessing pneumococcal meningitis association with viral
- 499 respiratory infections and antibiotics: insights from statistical and mathematical models,"
- 500 Proc. R. Soc. B Biol. Sci., vol. 280, no. 1764, p. 20130519, Aug. 2013, doi:
- 501 10.1098/rspb.2013.0519.
- 502 [5] A. Wu, V. T. Mihaylova, M. L. Landry, and E. F. Foxman, "Interference between
- 503 rhinovirus and influenza A virus: a clinical data analysis and experimental infection

504 study," *The Lancet Microbe*, vol. 1, no. 6, pp. e254–e262, 2020, doi:

505 https://doi.org/10.1016/S2666-5247(20)30114-2.

- 506 [6] F. Pinotti, F. Ghanbarnejad, P. Hövel, and C. Poletto, "Interplay between competitive and
- 507 cooperative interactions in a three-player pathogen system," *R. Soc. Open Sci.*, vol. 7, no.
- 508 1, p. 190305, Mar. 2022, doi: 10.1098/rsos.190305.
- 509 [7] M. Tin Tin Htar, M. S. Yerramalla, J. C. Moïsi, and D. L. Swerdlow, "The burden of

510 respiratory syncytial virus in adults: a systematic review and meta-analysis," *Epidemiol*.

511 *Infect.*, vol. 148, pp. e48–e48, Feb. 2020, doi: 10.1017/S0950268820000400.

- 512 [8] J. Nunes Caldeira Marinho Matos, S. Rodrigues Sousa, M. Braz, Y. Martins, and F.
- 513 Barata, "Characterization of influenza A, B and RSV infections in a Pulmonology ward
- 514 during the 17/18 flu-season," *Eur. Respir. J.*, vol. 54, no. suppl 63, p. PA4566, Sep. 2019,
- 515 doi: 10.1183/13993003.congress-2019.PA4566.

516	[9]	S. D. Meskill, P.	A. Revell, L.	Chandramohan, and A	. T. Cruz,	"Prevalence of co-
-----	-----	-------------------	---------------	---------------------	------------	--------------------

- 517 infection between respiratory syncytial virus and influenza in children," *Am. J. Emerg.*
- 518 *Med.*, vol. 35, no. 3, pp. 495–498, 2017, doi: https://doi.org/10.1016/j.ajem.2016.12.001.
- 519 [10] K. Bloom-Feshbach et al., "Latitudinal variations in seasonal activity of influenza and
- 520 respiratory syncytial virus (RSV): a global comparative review.," *PLoS One*, vol. 8, no. 2,
- 521 p. e54445, 2013, doi: 10.1371/journal.pone.0054445.
- 522 [11] A. Gordon and A. Reingold, "The Burden of Influenza: a Complex Problem.," Curr.
- 523 *Epidemiol. reports*, vol. 5, no. 1, pp. 1–9, 2018, doi: 10.1007/s40471-018-0136-1.
- 524 [12] M. Moghadami, "A Narrative Review of Influenza: A Seasonal and Pandemic Disease,"
- 525 Iran. J. Med. Sci., vol. 42, no. 1, pp. 2–13, Jan. 2017, [Online]. Available:
- 526 https://pubmed.ncbi.nlm.nih.gov/28293045.
- 527 [13] R. K. Virk et al., "Divergent evolutionary trajectories of influenza B viruses underlie their
- 528 contemporaneous epidemic activity," Proc. Natl. Acad. Sci., vol. 117, no. 1, pp. 619 LP -
- 529 628, Jan. 2020, doi: 10.1073/pnas.1916585116.
- 530 [14] M. I. Nelson et al., "Molecular Epidemiology of A/H3N2 and A/H1N1 Influenza Virus
- 531 during a Single Epidemic Season in the United States," *PLOS Pathog.*, vol. 4, no. 8, p.
- 532 e1000133, Aug. 2008, [Online]. Available: https://doi.org/10.1371/journal.ppat.1000133.
- 533 [15] B. Lu et al., "Emergence of new antigenic epitopes in the glycoproteins of human
- respiratory syncytial virus collected from a US surveillance study, 2015–17," Sci. Rep.,
- 535 vol. 9, no. 1, p. 3898, 2019, doi: 10.1038/s41598-019-40387-y.
- 536 [16] J. C. Muñoz-Escalante, A. Comas-García, S. Bernal-Silva, C. D. Robles-Espinoza, G.
- 537 Gómez-Leal, and D. E. Noyola, "Respiratory syncytial virus A genotype classification
- based on systematic intergenotypic and intragenotypic sequence analysis," Sci. Rep., vol.

- 539 9, no. 1, p. 20097, Dec. 2019, doi: 10.1038/s41598-019-56552-2.
- 540 [17] J. C. Muñoz-Escalante, A. Comas-García, S. Bernal-Silva, and D. E. Noyola, "Respiratory
- 541 syncytial virus B sequence analysis reveals a novel early genotype," *Sci. Rep.*, vol. 11, no.
- 542 1, p. 3452, 2021, doi: 10.1038/s41598-021-83079-2.
- 543 [18] S. Ascough, S. Paterson, and C. Chiu, "Induction and subversion of human protective
- 544 immunity: Contrasting influenza and respiratory syncytial virus," Frontiers in
- 545 *Immunology*, vol. 9, no. MAR. Frontiers Media S.A., p. 323, Mar. 02, 2018, doi:
- 546 10.3389/fimmu.2018.00323.
- 547 [19] G. Gonzàlez-Parra, F. De Ridder, D. Huntjens, D. Roymans, G. Ispas, and H. M.
- 548 Dobrovolny, "A comparison of RSV and influenza in vitro kinetic parameters reveals
- 549 differences in infecting time," *PLoS One*, vol. 13, no. 2, p. e0192645, Feb. 2018, [Online].

550 Available: https://doi.org/10.1371/journal.pone.0192645.

- 551 [20] N. R. Waterlow, S. Flasche, A. Minter, and R. M. Eggo, "Competition between RSV and
- 552 influenza: Limits of modelling inference from surveillance data," *Epidemics*, vol. 35, p.
- 553 100460, 2021, doi: https://doi.org/10.1016/j.epidem.2021.100460.
- 554 [21] G. Walzl, S. Tafuro, P. Moss, P. J. Openshaw, and T. Hussell, "Influenza virus lung
- 555 infection protects from respiratory syncytial virus-induced immunopathology," J. Exp.
- 556 *Med.*, vol. 192, no. 9, pp. 1317–1326, Nov. 2000, doi: 10.1084/jem.192.9.1317.
- 557 [22] L. van Asten et al., "Early occurrence of influenza A epidemics coincided with changes in
- 558 occurrence of other respiratory virus infections," *Influenza Other Respi. Viruses*, vol. 10,
- 559 no. 1, pp. 14–26, Jan. 2016, doi: 10.1111/irv.12348.
- 560 [23] L. Opatowski, M. Baguelin, and R. M. Eggo, "Influenza interaction with cocirculating
- 561 pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role

562	or mathematical modelling," <i>PLOS Pathog.</i> , vol. 14, no. 2, p. e1006770, Feb. 201	8.
001	$c_1 maintennation modelning, 1 2001 mmodel, c_1, c_1, c_2, c_1, c_1, c_2, c_2, c_1, c_2, c_2, c_1, c_2, c_1, c_2, c_2, c_2, c_2, c_2, c_2, c_2, c_2$	~,

- 563 [Online]. Available: https://doi.org/10.1371/journal.ppat.1006770.
- 564 [24] G. Walzl, S. Tafuro, P. Moss, P. J. Openshaw, and T. Hussell, "Influenza virus lung
- 565 infection protects from respiratory syncytial virus-induced immunopathology," J. Exp.
- 566 *Med.*, vol. 192, no. 9, pp. 1317–1326, Nov. 2000, doi: 10.1084/jem.192.9.1317.
- 567 [25] S. M. Hartwig, A. M. Miller, and S. M. Varga, "Respiratory Syncytial Virus Provides
- Protection against a Subsequent Influenza A Virus Infection," *J. Immunol.*, vol. 208, no. 3,
  pp. 720 LP 731, Feb. 2022, doi: 10.4049/jimmunol.2000751.
- 570 [26] Y. Drori et al., "Influenza A Virus Inhibits RSV Infection via a Two-Wave Expression of
- 571 IFIT Proteins.," Viruses, vol. 12, no. 10, Oct. 2020, doi: 10.3390/v12101171.
- 572 [27] B. Justin et al., "Temporally structured metapopulation dynamics and persistence of
- 573 influenza A H3N2 virus in humans," Proc. Natl. Acad. Sci., vol. 108, no. 48, pp. 19359–
- 574 19364, Nov. 2011, doi: 10.1073/pnas.1109314108.
- 575 [28] L. Staadegaard et al., "Defining the seasonality of respiratory syncytial virus around the
- 576 world: National and subnational surveillance data from 12 countries.," *Influenza Other*

577 *Respi. Viruses*, vol. 15, no. 6, pp. 732–741, Nov. 2021, doi: 10.1111/irv.12885.

- 578 [29] E. Grilc, K. Prosenc Trilar, J. Lajovic, and M. Sočan, "Determining the seasonality of
- 579 respiratory syncytial virus in Slovenia," *Influenza Other Respi. Viruses*, vol. 15, no. 1, pp.
- 580 56–63, Jan. 2021, doi: https://doi.org/10.1111/irv.12779.
- 581 [30] Y. Li, X. Wang, E. K. Broberg, H. Campbell, and H. Nair, "Seasonality of respiratory
- 582 syncytial virus and its association with meteorological factors in 13 European countries,
- 583 week 40 2010 to week 39 2019.," Euro Surveill. Bull. Eur. sur les Mal. Transm. = Eur.
- 584 *Commun. Dis. Bull.*, vol. 27, no. 16, Apr. 2022, doi: 10.2807/1560-

585 7917.ES.2022.27.16.2100619.

- 586 [31] M. Robertson et al., "The spatial-temporal dynamics of respiratory syncytial virus
- 587 infections across the east–west coasts of Australia during 2016–17," Virus Evol., vol. 7,
- 588 no. 2, p. veab068, Dec. 2021, doi: 10.1093/ve/veab068.
- 589 [32] H. Chi, K.-L. Hsiao, L.-C. Weng, C.-P. Liu, and H.-F. Liu, "Persistence and continuous
- 590 evolution of the human respiratory syncytial virus in northern Taiwan for two decades,"
- *Sci. Rep.*, vol. 9, no. 1, p. 4704, 2019, doi: 10.1038/s41598-019-41332-9.
- 592 [33] J. Schwarze, D. R. O'Donnell, A. Rohwedder, and P. J. M. Openshaw, "Latency and
- 593 Persistence of Respiratory Syncytial Virus Despite T Cell Immunity," Am. J. Respir. Crit.
- 594 *Care Med.*, vol. 169, no. 7, pp. 801–805, Apr. 2004, doi: 10.1164/rccm.200308-1203OC.
- 595 [34] D. Zinder, T. Bedford, S. Gupta, and M. Pascual, "The Roles of Competition and
- 596 Mutation in Shaping Antigenic and Genetic Diversity in Influenza," *PLOS Pathog.*, vol. 9,
- 597 no. 1, p. e1003104, Jan. 2013, [Online]. Available:
- 598 https://doi.org/10.1371/journal.ppat.1003104.
- 599 [35] T. Bedford, S. Cobey, and M. Pascual, "Strength and tempo of selection revealed in viral
- 600 gene genealogies.," *BMC Evol. Biol.*, vol. 11, p. 220, Jul. 2011, doi: 10.1186/1471-2148-
- 601 11-220.
- 602 [36] T. Bedford *et al.*, "Global circulation patterns of seasonal influenza viruses vary with
  603 antigenic drift," *Nature*, vol. 523, no. 7559, pp. 217–220, Jul. 2015, doi:
- 604 10.1038/nature14460.
- 605 [37] T. M. Paiva *et al.*, "Shift in the timing of respiratory syncytial virus circulation in a
- 606 subtropical megalopolis: implications for immunoprophylaxis.," J. Med. Virol., vol. 84,
- 607 no. 11, pp. 1825–1830, Nov. 2012, doi: 10.1002/jmv.23347.

- 608 [38] L. Pinky and H. M. Dobrovolny, "Coinfections of the Respiratory Tract: Viral
- 609 Competition for Resources," *PLoS One*, vol. 11, no. 5, p. e0155589, May 2016, [Online].
- 610 Available: https://doi.org/10.1371/journal.pone.0155589.
- 611 [39] K. L. Laurie et al., "Interval Between Infections and Viral Hierarchy Are Determinants of
- 612 Viral Interference Following Influenza Virus Infection in a Ferret Model," J. Infect. Dis.,
- 613 vol. 212, no. 11, pp. 1701–1710, Dec. 2015, doi: 10.1093/infdis/jiv260.
- 614 [40] N. R. Waterlow et al., "Evidence for influenza and RSV interaction from 10 years of
- 615 enhanced surveillance in Nha Trang, Vietnam, a modelling study," *PLOS Comput. Biol.*,
- 616 vol. 18, no. 6, p. e1010234, Jun. 2022, [Online]. Available:
- 617 https://doi.org/10.1371/journal.pcbi.1010234.
- 618 [41] S. Ascough, S. Paterson, and C. Chiu, "Induction and Subversion of Human Protective
- 619 Immunity: Contrasting Influenza and Respiratory Syncytial Virus.," *Front. Immunol.*, vol.
- 620 9, p. 323, 2018, doi: 10.3389/fimmu.2018.00323.
- 621 [42] Y. Yang et al., "Influenza A/H1N1 2009 Pandemic and Respiratory Virus Infections,
- 622 Beijing, 2009–2010," *PLoS One*, vol. 7, no. 9, p. e45807, Sep. 2012, [Online]. Available:
- 623 https://doi.org/10.1371/journal.pone.0045807.
- 624 [43] P. Rohani, D. J. Earn, B. Finkenstädt, and B. T. Grenfell, "Population dynamic
- 625 interference among childhood diseases," Proc. R. Soc. London. Ser. B Biol. Sci., vol. 265,
- 626 no. 1410, pp. 2033–2041, Nov. 1998, doi: 10.1098/rspb.1998.0537.
- 627 [44] S. J. Olsen *et al.*, "Changes in Influenza and Other Respiratory Virus Activity During the
- 628 COVID-19 Pandemic United States, 2020-2021," MMWR. Morb. Mortal. Wkly. Rep.,
- 629 vol. 70, no. 29, pp. 1013–1019, Jul. 2021, doi: 10.15585/mmwr.mm7029a1.
- 630 [45] D. H. Charbonneau and L. N. James, "FluView and FluNet: Tools for Influenza Activity

- 631 and Surveillance," Med. Ref. Serv. Q., vol. 38, no. 4, pp. 358–368, Oct. 2019, doi:
- 632 10.1080/02763869.2019.1657734.
- 633 [46] "State Population Totals: 2010-2019." https://www.census.gov/data/tables/time-
- 634 series/demo/popest/2010s-state-total.html (accessed Jul. 04, 2022).
- 635 [47] "Time Series Analysis and Its Applications: With R Examples tsa4."
- 636 https://www.stat.pitt.edu/stoffer/tsa4/ (accessed Jul. 04, 2022).
- 637 [48] S. Kim, T. C. Williams, C. Viboud, H. Campbell, J. Chen, and D. J. Spiro, "RSV genomic
- diversity and the development of a globally effective RSV intervention," *Vaccine*, vol. 39,
- 639 no. 21, pp. 2811–2820, 2021, doi: https://doi.org/10.1016/j.vaccine.2021.03.096.
- 640 [49] S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman, "Basic local
- 641 alignment search tool.," J. Mol. Biol., vol. 215, no. 3, pp. 403–410, Oct. 1990, doi:
- 642 10.1016/S0022-2836(05)80360-2.
- 643 [50] K. Katoh and D. M. Standley, "MAFFT multiple sequence alignment software version 7:
- 644 improvements in performance and usability," Mol. Biol. Evol., vol. 30, no. 4, pp. 772–780,
- 645 Apr. 2013, doi: 10.1093/molbev/mst010.
- 646 [51] A. Stamatakis, "RAxML version 8: a tool for phylogenetic analysis and post-analysis of

647 large phylogenies," *Bioinformatics*, vol. 30, no. 9, pp. 1312–1313, May 2014, doi:

- 648 10.1093/bioinformatics/btu033.
- 649 [52] "Exploring the temporal structure of heterochronous sequences using TempEst (formerly
- 650 Path-O-Gen)." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989882/ (accessed Aug.
  651 07, 2020).
- [53] B. Q. Minh, S. Klaere, and A. von Haeseler, "Taxon Selection under Split Diversity.,"
- 653 *Syst. Biol.*, vol. 58, no. 6, pp. 586–594, Dec. 2009, doi: 10.1093/sysbio/syp058.

- 654 [54] M. A. Suchard, P. Lemey, G. Baele, D. L. Ayres, A. J. Drummond, and A. Rambaut,
- 655 "Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10," *Virus*
- 656 *Evol.*, vol. 4, no. 1, Jan. 2018, doi: 10.1093/ve/vey016.
- 657 [55] S. Tavaré and others, "Some probabilistic and statistical problems in the analysis of DNA
- 658 sequences," Lect. Math. life Sci., vol. 17, no. 2, pp. 57–86, 1986.
- 659 [56] B. Shapiro, A. Rambaut, and A. J. Drummond, "Choosing appropriate substitution models
- 660 for the phylogenetic analysis of protein-coding sequences," *Mol. Biol. Evol.*, vol. 23, no.
- 661 1, pp. 7–9, Jan. 2006, doi: 10.1093/molbev/msj021.
- 662 [57] V. N. Minin, E. W. Bloomquist, and M. A. Suchard, "Smooth Skyride through a Rough
- 663 Skyline: Bayesian Coalescent-Based Inference of Population Dynamics," *Mol. Biol. Evol.*,

664 vol. 25, no. 7, pp. 1459–1471, Jul. 2008, doi: 10.1093/molbev/msn090.

- 665 [58] A. Rambaut, A. J. Drummond, D. Xie, G. Baele, and M. A. Suchard, "Posterior
- 666 Summarization in Bayesian Phylogenetics Using Tracer 1.7," *Syst. Biol.*, vol. 67, no. 5,
- 667 pp. 901–904, Sep. 2018, doi: 10.1093/sysbio/syy032.
- 668 [59] S. Shrestha, A. A. King, and P. Rohani, "Statistical Inference for Multi-Pathogen
- 669 Systems," *PLOS Comput. Biol.*, vol. 7, no. 8, p. e1002135, Aug. 2011, [Online].
- 670 Available: https://doi.org/10.1371/journal.pcbi.1002135.
- 671 [60] C. Y. Lin, "Modeling Infectious Diseases in Humans and Animals by KEELING, M. J.
- 672 and ROHANI, P.," *Biometrics*, vol. 64, no. 3, p. 993, Sep. 2008, doi:
- 673 https://doi.org/10.1111/j.1541-0420.2008.01082\_7.x.
- 674 [61] A. A. King, D. Nguyen, and E. L. Ionides, "Statistical Inference for Partially Observed
- 675 Markov Processes via the R Package pomp," J. Stat. Softw., vol. 69, no. 12 SE-Articles,
- 676 pp. 1–43, Mar. 2016, doi: 10.18637/jss.v069.i12.

- 677 [62] S. J. Olsen *et al.*, "Changes in Influenza and Other Respiratory Virus Activity During the
- 678 COVID-19 Pandemic United States, 2020-2021," MMWR. Morb. Mortal. Wkly. Rep.,
- 679 vol. 70, no. 29, pp. 1013–1019, Jul. 2021, doi: 10.15585/mmwr.mm7029a1.